SCHEMBL2904815

SCHEMBL2904815

COc1ccc(N(Cc2cccnc2)c2cccc(Cl)c2)nc1O[C@@H]1CCOC1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 5/20 0.38
PDE4D Q08499 5/20 0.38
PDE4A P27815 5/20 0.38
PDE4C Q08493 4/20 0.38
MAPK1 P28482 1/20 0.38
PTGER2 P43116 1/20 0.38
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 1/20 0.36
SLC6A4 P31645 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
CHEK1 O14757 1/20 0.35
PTAFR P25105 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908190 0.90 PDE4D (0.42) PDE4BPDE4DPDE4APDE4CTP53
SCHEMBL1157321 0.87 PDE4D (0.46) PDE4BPDE4DPDE4APDE4CMAPK1
SCHEMBL2902489 0.87 PDE4D (0.44) PDE4BPDE4DPDE4APDE4CTP53
SCHEMBL2910468 0.87 PDE4D (0.44) PDE4BPDE4DPDE4APDE4CTP53
SCHEMBL8284049 0.84 PTGER2 (0.38) PDE4BPDE4DPDE4APDE4CMAPK1
SCHEMBL2901989 0.81 PDE4D (0.42) PDE4BPDE4DPDE4APDE4CTP53
SCHEMBL2901842 0.80 PDE4D (0.38) PDE4BPDE4DPDE4APDE4CTP53
SCHEMBL2908119 0.80 XDH (0.36) PDE4BPDE4DPDE4APDE4CALDH1A1
SCHEMBL1157823 0.78 PDE4D (0.53) PDE4BPDE4DPDE4APDE4CALDH1A1
SCHEMBL2905268 0.78 PDE4A (0.47) PDE4BPDE4DPDE4APDE4CTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP claimed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US claimed
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B PDE4B 2/4885PDE4D 6/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.